Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting

David G. Strauss, Gary Gintant, Zhihua Li, Wendy Wu, Ksenia Blinova, Jose Vicente, J. Rick Turner, Philip T. Sager

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

A Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA-sponsored Think Tank Meeting was convened in Washington, DC, on May 21, 2018, to bring together scientists, clinicians, and regulators from multiple geographic regions to evaluate progress to date in the Comprehensive In Vitro Proarrhythmia Assay (CiPA) Initiative, a new paradigm to evaluate proarrhythmic risk. Study reports from the 4 different components of the CiPA paradigm (ionic current studies, in silico modeling to generate a Torsade Metric Score, human induced pluripotent stem cell–derived ventricular cardiomyocytes, and clinical ECG assessments including J-Tpeakc) were presented and discussed. This paper provides a high-level summary of the CiPA data presented at the meeting.

Original languageEnglish (US)
JournalTherapeutic Innovation and Regulatory Science
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

    Fingerprint

Keywords

  • balanced ion channel-blocking drugs
  • CiPA
  • human induced pluripotent stem cell-derived ventricular cardiomyocytes
  • J-Tpeakc
  • torsade de pointes
  • torsade metric score

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this